ストックスクリーナーアプリを入手
0.9696
3.04%
-0.0304
前日終値:
$1.00
開ける：
$0.99
24時間の取引高:
105.15K
Relative Volume:
0.42
時価総額：
$98.63M
収益：
-
当期純損益:
$-19.50M
株価収益率:
-6.3789
EPS:
-0.152
ネットキャッシュフロー:
$-19.09M
1週間 パフォーマンス:
+4.90%
1か月 パフォーマンス:
+12.11%
6か月 パフォーマンス:
+18.24%
1年 パフォーマンス:
+67.20%
1日の値動き範囲:
$0.95
$1.00
1週間の範囲:
$0.875
$1.07
52週間の値動き範囲:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| TLSA | 0.9696 | 98.63M | 0 | -19.50M | -19.09M | -0.152 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.25 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.84 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2018-12-17 | 開始されました | Laidlaw | Buy |
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Tiziana Life Sciences secures grant for ALS trial - Proactive financial news
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - The Manila Times
Tiziana Life Sciences Secures ALS Association Grant for Breakthrough Foralumab Trial | TLSA Stock News - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short Interest - MarketBeat
Tiziana Life Sciences CEO discusses foralumab potential to enhance OzempicICYMI - Proactive Investors USA
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - The Manila Times
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference - Proactive Investors UK
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer’s therapy - Proactive Investors USA
Tiziana Life Sciences Plans Share Sale with Jefferies - MSN
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study - GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - The Manila Times
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - GlobeNewswire Inc.
Tiziana reports progress in obesity inflammation study By Investing.com - Investing.com South Africa
Tiziana Life Sciences : announces plans for clinical development of foralumab, the company’s fully human CD3 antibody - Marketscreener.com
Tiziana Life Sciences' Semaglutide combo shows potential in obesity-related liver inflammation - Proactive Investors USA
TLSATiziana Life Sciences Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity - Proactive Investors UK
Tiziana reports progress in obesity inflammation study - Investing.com
Proactive news headlines: Helix, Hemogenyx, DEC, Ananda, Thor Energy, Bradda Head and more - Proactive Investors UK
Discover October 2024's Promising US Penny Stocks - Simply Wall St
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Tiziana Life Sciences Advances with Promising Drug Trials - Yahoo Finance
Tiziana Life Sciences reports interim results, updates on programs - Investing.com India
Tiziana Life Sciences reports interim results, updates on programs By Investing.com - Investing.com Canada
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update - MarketBeat
High Affinity Nerve Growth Factor Receptor Market constantly growing to See Bigger Picture - IndiaPolitics.com
Thymic Carcinoma Treatment Market Size, Market Resilience and Forecasted Scenarios (2024-2034) - Third Eye News
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Declines By 67.0% - MarketBeat
Base Resources Limited (OTCMKTS:BSRUF) Sees Significant Increase in Short Interest - Defense World
Tiziana Life Sciences Secures $4M Grant for Alzheimer’s Disease Study - European Pharmaceutical Manufacturer
EverSource Wealth Advisors LLC Acquires 330,000 Shares of Signing Day Sports, Inc. (NYSEAMERICAN:SGN) - Defense World
New Pacific Mtl to Post Q1 2025 Earnings of $0.00 Per Share, Raymond James Forecasts (TSE:NUA) - Defense World
iShares ESG Aware MSCI USA ETF (NASDAQ:ESGU) Stock Holdings Lifted by Affinity Capital Advisors LLC - Defense World
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Affinity Capital Advisors LLC Has $4.62 Million Position in Vanguard Short-Term Bond ETF (NYSEARCA:BSV) - Defense World
ENN Energy Holdings Limited (OTCMKTS:XNGSY) Short Interest Up 550.0% in September - Defense World
Thrivent Financial for Lutherans Cuts Holdings in Regal Rexnord Co. (NYSE:RRX) - Defense World
AlTi Global Inc. Sells 1,052 Shares of CVS Health Co. (NYSE:CVS) - Defense World
Tiziana Life Sciences Ltd: Analyzing TLSA Stock Trends - The InvestChronicle
JPMorgan Chase & Co. Initiates Coverage on Alcoa (NYSE:AA) - Defense World
Tesla's Massive October Starts Next Week With Third-Quarter Deliveries - MSN
CRH plc (NYSE:CRH) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Increase in Short Interest - Defense World
Tesla's Robotaxi Launch: A Game-Changer For Stock Performance? - MSN
Tesla (TSLA) call put ratio 2.1 calls to 1 put with focus on October 285 and 325 calls into deliveries release for Q3 and Robotaxi meeting - StreetInsider.com
Commonwealth Financial Services LLC Acquires 95 Shares of Tesla, Inc. (NASDAQ:TSLA) - Defense World
Tesla: stock outperforms, buoyed by optimism from UBS - Marketscreener.com
Analysts praise groundbreaking Tesla rival, previews Robotaxi event - MSN
Tesla Stock Pops 5% To 2-Month High As Q3 Deliveries, Robotaxi Event Await - MSN
Edge Capital Group LLC Acquires New Holdings in Tesla, Inc. (NASDAQ:TSLA) - Defense World
Tiziana Life Sciences Ltd (TLSA) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):